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Summary 
Although very similar in sequence, the four subclasses of human immunoglobulin G (IgG) differ 
markedly in their ability to activate complement. Glu318-Lys320-Lys322 has been identified as 
a key binding motif for the first component of complement, Clq, and is present in all isotypes 
of Ig capable of activating complement. This motif, however, is present in all subclasses of human 
IgG, including those that show little (IgG2)  or even no (IgG4)  complement activity.  Using 
point mutants of chimeric antibodies, we have identified specific  residues responsible for the differing 
ability of the IgG subclasses to fix complement. In particular, we show that Ser at position 331 
in 3/4 is critical for determining the inability of that isotype to bind Clq and activate complement. 
Additionally, we provide further evidence that levels of Clq binding do not necessarily correlate 
with levels of complement activity, and that Clq binding alone is not sufficient for complement 
activation. 
T 
he classical pathway of complement activation is initi- 
ated by immune complexes composed of antigen and ei- 
ther IgM or IgG Abs. Although the C region domains of 
all four human IgG subclasses share virtually identical amino 
acid sequences, they differ markedly in their ability to acti- 
vate complement. Studies of mouse-human chimeric Abs have 
shown that IgG3 and IgG1 are effective in activating com- 
plement, IgG2 fixes complement poorly,  and IgG4 appears 
completely defcient in the ability to activate complement (1, 
2). The structural bases for these isotype-specific differences 
in complement activation have not been defined and are the 
subject  of this investigation. 
The hinge region, which separates the Fab from the Fc, 
has been implicated in determining these isotypic differences 
in part because the sequences of the hinge regions, in con- 
trast  to the other C region domains of the 3' isotypes, are 
remarkably diverse (2, 3) and also because two hinge-deleted 
human IgG1 myeloma proteins lost both the ability to acti- 
vate complement and to bind its first component, C1 (4). 
Additionally, hinge length and Fab arm segmental flexibility 
of IgG Abs from different  species were found to correlate 
with the ability to activate complement (2, 5). Recently, how- 
ever, we and others (6, 7) using genetically engineered Abs 
have shown that whereas a hinge region is essential for Clq 
binding and complement activation,  the hinge does not ap- 
pear to determine isotypic differences in these functions, and 
there is not an absolute correlation between segmental flexi- 
bility and the ability to activate complement. An IgG3 with 
the rigid hinge of IgG4 exhibits significant complement ac- 
tivation ability and an IgG4 with the hinge of IgG3, although 
as flexible as wild-type IgG3, displays no detectable comple- 
ment activity. It thus appears that it is not the short, inflex- 
ible hinge but other structural features located in the H chain 
that lead to the inactivity of IgG4. 
C.2 has been implicated as the domain responsible for iso- 
typic differences  in complement fixation. Earlier Ab fragmen- 
tation studies (8-10) suggested a crucial role for C.2 in ac- 
tivating complement by showing that Fab (IgG depleted of 
CH3) and C.2 fragments bind C1 and activate complement, 
whereas Fab and C.3 fragments do not show any activity. 
Moreover, aglycosylated  IgG (lacking carbohydrate side chains 
in C.2) is unable to activate complement (1I, 12). Domain- 
shuffled chimeric Abs provide further direct evidence that 
the isotypic variations in complement activity are determined 
by this domain. IgG2 with the C.2 domain from IgG3 per- 
forms complement-mediated cell lysis almost as well as wild- 
type IgG3, and the replacement  of C.2 in IgG3 with the 
corresponding domain from IgG2 decreases its capacity to 
fix complement to a level comparable with that of wild-type 
IgG2 (13). By contrast, the exchange of C.1 or C.3 domains 
has no effect on complement activation  (7,  13). Studies of 
domain switch Abs of murine IgG subclasses also confirmed 
the importance of C.2 in determining the isotypic  differ- 
ences (14). We further localized the structural features leading 
to the inactivity of human IgG4 to the COOH-terminal part 
of C.2, from residues 292 to 340 (13). 
In the present study we identify specific  polymorphic amino 
acids in the C.2 domain of human IgG that account for sub- 
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duced into chimeric IgG1, IgG3, or IgG4 show that the pres- 
ence of Ser instead of Pro at residue 331 in wild-type IgG4 
contributes significantly to its inability to bind Clq and acti- 
vate complement. In addition, we provide evidence that sub- 
stitutions at residues 276  and 291 can influence the ability 
to activate complement, although apparently not by affecting 
Clq binding, suggesting the involvement of additional Ab- 
dependent steps in the classical pathway of complement ac- 
tivation.  Other polymorphic residues  in C.2 are  also dis- 
cussed. 
Materials and Methods 
In  Vitro Mutagenesis and  Construction of Chimeric IgG Mole- 
cules.  The expressed Vx and VH genes from the  mouse anti- 
dansyl (DNS)  1  hybridoma 27-44 were joined to human CK in the 
pSV2AHneo expression vector and to human IgG H chain in the 
pSV2AHgpt vector, respectively (15). The human genomic ~/C 
region genes were cloned as SalI/BamHI cassettes. This makes it 
convenient to shuffle the genes between different ptasmids and to 
join different H chain genes to the same V.. 
The SalI/BamHI cassettes containing human C3' genes were 
cloned into the polylinker region of M13mp18 or M13mp19 for 
mutagenesis. To construct the intra-C,2  domain switch variants 
of IgG1 and IgG4, the cloned IgG genes were digested with Sail 
and SaclI (which cleaves within C.2) and the SalI/SacII fragments 
were reciprocally  exchanged  between 3/1 and 3~4. Oligonucleotide- 
mediated site-directed mutagenesis was done based on the two- 
primer method of Zoller and Smith (16) with modifications and 
the mutations confirmed by sequencing. 
Production of Transfectoma Proteins.  P3X63Ag8.653, an Ig non- 
producing mouse mydoma  cell  line, was transfected  simultaneously 
with the H and L chain expression vectors by dectroporation (17). 
Transfectants were selected with G418 (Gibco, Grand Island, NY) 
at 1.0 ms/m1, and surviving clones were screened for Ab produc- 
tion by ELISA  using DNS/BSA-coated  plates. The amount of  bound 
chimeric Ab was determined  using alkaline  phosphatase-conjugated 
polyclonal  goat Ab (Sigma Chemical Co., St. Louis, MO) against 
human IgG C regions. Clones producing large quantities of anti- 
DNS Ab were expanded and maintained in IMDM containing 5% 
calf serum. Chimeric Abs were purified by DNS-coupled affinity 
chromatography as described previously (12). The concentrations 
of  purified Abs were determined by a bicinchoninic  acid-based  pro- 
tein assay (BCA; Pierce, Rockford, IL). 
Complement-mediated Hemolysis.  SILBC  were coated  with DNS- 
BSA (0.25 mg/ml DNS-BSA, 5% SR.BC, in 150 mM NaC1, 0.25 
mM CrC13, pH  7.0, for  1 h  at  30~  and loaded with SlCr- 
sodium chromate (Amersham Corp., Arlington Heights, IL). The 
free SlCr-sodinm  chromate was removed  by washing the cells three 
times in 10 ml of fresh geI-HBSS buffer (0.01 M Hepes, 0.15 M 
NaC1, 0.5 mM MgCI2, 0.15 mM CaC12, and 0.1% gelatin, pH 
7.4). Chimeric Abs in geI-HBSS at various concentrations were 
added to round-bottomed, 96-weU plates (Corning Glass Works, 
Coming, NY) in a volume of 50/~1. Then 50 #1 of 2% SlCr- 
loaded SRBC and 10 times the amount of guinea pig complement 
(Colorado Serum Co., Denver, CO) required to produce lysis of 
50% of the cells, preabsorbed  against unlabeled  SR.SC, in a volume 
of 25/~1 were added to each well sequentially.  The plates were in- 
cubated at 370C for 45 min, unlysed StLBC were pelleted by cen- 
1  Abbreviations used in this paper: DNS, dansyl. 
trifugation of  the plate, and 50/~1 of supernatant  counted in a gamma 
counter. Each point was assayed  in triplicate and the percent lysis 
calculated. For Abs that contained a mutation that restored activity, 
multiple protein preparations were analyzed. 
C1q Binding.  All steps were carried out in HBSS plus 0.02% 
sodium azide and plates were washed six times between each step 
with the same  buffer.  96-weU plates (Immulon-2; Dynatech Labora- 
tories Inc., Chantilly, VA) were coated with 100 #l/well DNS- 
BSA (40:1 substitution ratio, 10/~g/ml,  overnight at 4~  then 
blocked with 200/~l/well 3% BSA (overnight at 4~  All Abs 
were diluted in 1% BSA, applied in a volume of 100/~l/well, and 
incubated at room temperature for 2 h or overnight at 4~  All 
assays were carried out in quadruplicate. First, anti-DNS Abs were 
bound at a concentration of 20 #g/ml. The plates were washed 
and normal human serum diluted to 0.25% was applied  in a volume 
of 100 #1 at 37~  for 2 h. The detecting Ab was goat anti-human 
Clq (Atlantic Antibodies, Stillwater, MN) diluted 1:10,000, and 
the developing agent was swine anti-goat IgG-alkaline phospha- 
tase conjugate (Boehringer Mannheim, Indianapolis, IN) diluted 
1:20,000. 100/~1 p-nitrophenyl phosphate (Sigma Chemical Co.) 
at 0.5 mg/ml in diethanolamine was added as phosphatase sub- 
strate, and the OD read at 410 nm. 
Results 
Our previous domain switch experiments clearly demon- 
strated that the CH2 domain of IgG contains sites important 
for interacting with Clq and initiating activation of the com- 
plement cascade (13). Human IgG1, IgG3, and IgG4 exhibit 
very few polymorphisms in their C~2 domains (Table 1), but 
differ profoundly in their ability to activate complement by 
the classical pathway. We set out to establish  which amino 
acid polyporphisms determine the isotype-specific differences 
in complement activation. To address this question, a set of 
Table  1.  Polymorphisms  in C,2 among IgG1, IgG3, 
and lgG4 
Residue  IgG1  IgG3  IgG4 
234*  Leu*  Leu  Phe 
268  His  His  Gln 
274  Lys  Gln  Gln 
276  Asn  Lys  Asn 
291  Pro  Leu  Pro 
296  Tyr  Tyr  Phe 
300  Tyr  Phe  Tyr 
327  Ala  Ala  Gly 
330  Ala  Ala  Ser 
331  Pro  Pro  Ser 
* Residue number is based on the EU numbering system. 
*Sequences of IgG subclasses are taken from Kabat et  al.  (3)  and 
confirmed by sequence analysis of the H chain genes used in these ex- 
periments. 
(-) Position of C.2 exchange in IgG (1/4) and IgG (4/1) hybrid 
proteins. 
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Region E.xons 
Name  CHI  H  Cta2  Crt3  Description 
IgG 1  I  Wild type lgG 1 
IgGl(Lys276)  I  T  I  IgGI Asn276--)Lys 
lgG I(Leu29X)  |  T  lgGl Pro291  --->Leu 
IgG l(Ser330)  II  T  lgGl Ala330-->Ser 
IgG l(Ser331)  II  ~  lgGl Pro33 l--+Ser 
IgG3  Wild type lgG3 
IgG3(Asn276)  .....  ""  ~  ms  - -- ~  IgO3 Lys276--->Asn 
IgG3(Ser331)  ~  ~.  --..--~_'-r  IgG3 Pro331-/,Ser 
lgG4  -'1  I-0"t  I"1  I"  Wild type IgG4 
IgG4(Tyr296)  "1  ~  I-'I  t"  IgG4 Phe296-~Tyr 
lgG4(Ala330)  -I  ~  ~M  I-  IgG4 Ser330---)Ala 
IgG4(Pro331)  "-I  ~  ~l-I  '" ]-  IgG4 Ser331--~Pro 
IgG(4/X)  -'1  ~  4,4,4/1-1 hybrid 
lgG(l/4)  ~  I"  I  ￿9 D, 1/4,,4 hybrid 
IgG 1/4 (Pro331)  ~  ,1"-  IgG(l/4) Ser331---)Pro 
(~2) Location of mutated amino adds. 
mouse-human chimeric Abs having identical antigen-com- 
bining sites (anti-DNS) and L chains but with different H 
chain C region domains were generated using previously de- 
scribed techniques (15, 18). The point mutations were made 
in the context of either wild-type human 3/1, 3'3, 3,4, or a 
C  region in which yl and 3'4 were shuffled at amino acid 
292, as described previously (13). The names of the mutant 
proteins and the amino acids mutated in their C.2 domains 
are shown in Table 2. All chimeric Abs were purified from 
culture supernatants using DNS isomer affinity chromatog- 
raphy (12) and used in the complement-mediated hemolysis 
and Clq binding assays. 
Analysis of  Residues Polymorehic between IgGI and lgG3.  In 
previous studies we have consistently found anti-DNS IgG3 
to be about 10 times more effective than IgG1 in comple- 
ment consumption and complement-mediated cell lysis (2, 
12). Within the C,2 domain, human IgG1 and IgG3 differ 
from each other at only four residues: 274 (Lys vs. Gln), 276 
(Asn vs. Lys), 291 (Pro vs. Leu), and 300 (Tyr vs. Phe) (Table 
1). We focused our attention on the polymorphisms  at residues 
276 and 291. Indeed, we find that substitution of Lys276 with 
Asn in IgG3 (IgG3[Asn276]) reduces its ability to activate 
complement to a level comparable with that seen in IgG1 
(Fig.  1). However, the reciprocal  mutation, Asn 276---Lys 
in IgG1 (IgG1[Lys276]), does not improve its ability to acti- 
vate complement but instead results in a protein with im- 
paired ability. Therefore, whereas the Lys 276+Asn substi- 
tution can make IgG3 functionally similar to IgG1 in its ability 
to activate complement, none of the single amino acid changes 
tested suffice to improve IgG1 to the level of IgG3. 
There was a lack of correlation between the ability of the 
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Complement-mediated  hemolysis  by wild-type  and point  mu-  Figure  1. 
tants of IgG1 and lgG3. stCr-loaded, DNS-BSA-coated SRBC were in- 
cubated with varying concentrations of Ab in the presence of guinea pig 
complement and percent cell lysis calculated. IgG3 mutated to resemble 
lgG1 at position 276 shows an activity reduced approximately to the level 
of wild-type IgG1. IgG3-1ike mutants of IgG1 however, do not show in- 
creased complement activity, rather they too are impaired relative to wild 
type￿9 
Abs to carry out complement-mediated  hemolysis and their 
ability to bind Clq. However, it should be noted that whereas 
guinea pig complement was used in the direct lysis assay, 
human complement was used to measure Clq binding. IgG3 
was consistently more effective than IgG1 in complement- 
mediated hemolysis (Fig. 1), but both isotypes were equiva- 
lent in their ability to bind Clq (Fig. 2). The result obtained 
in the current study differs slightly from our previously ob- 
servation that IgG3 was seen to bind Clq better than IgG1 
(12). However,  a different version of the Clq binding assay 
was used in the earlier study. It is interesting that whereas 
exchanging residues at position 276 in IgG1 and IgG3 dearly 
affects both molecules negatively in overall complement ac- 
tivation, neither mutation significantly affects Clq binding 
(Fig. 2). IgGl(Leu291), also binds Clq as welt as wild type, 
but is impaired in the direct lysis assay. 
Role of Pro331.  IgG4 is unable to activate complement 
or bind Clq, a deficiency that can be localized to the COOH 
terminus of C.2 (13). These studies had shown that the hy- 
brid protein IgG1/4, in which the C region switches from 
IgG1 to IgG4 at amino acid 292, is unable to activate com- 
plement whereas IgG4/1, the molecule with the reciprocal 
exchange, can, albeit not as well as IgG1. Within C.2, the 
IgG1/4 protein differs from IgG1 at four residues:  Phe296 
instead of Tyr, Gly327 instead of Ala, Set330 instead of Ala, 
and Ser331 instead of Pro. The Set/Pro polymorphism at res- 
idue 331 seemed to be a good candidate for contributing to 
the differences in activity, both because of the nature of the 
substitution and because of the position of Pro exposed on 
the surface of the protein (Fig. 3). Indeed, we find that sub- 
stitution of Pro at position 331 in IgG4 (IgG4[Pro331]) results 
in a molecule that can now bind Clq and mediate complement- 
directed lysis (Figs. 2 and 4 A). When this substitution is 
made in the context of the IgG1/4 protein, the resulting mol- IgGl 
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Figure 2.  Clq binding  by wild-type and point mutants of IgG1, IgG3, 
IgG4, and the 1/4 hybrid proteins. Clq bound to Ag-Ab complexes on 
a microtiter dish was detected with goat anti-Clq Ab and swine anti-goat 
IgG conjugated to alkaline phosphatase. Substitution  of Pro for Set at po- 
sition 331 in IgG4 and the IgG1/4 hybrid results in Abs now capable of 
binding  Clq (ll). The reciprocal  mutation  in IgG1 and IgG3 greatly reduces 
their ability  to bind Clq although only to the level of the Pro331 mutants 
of IgG4 and IgG1/4 ([]). Our mutations at positions 276, 291, 296, and 
330 in IgG1, IgG3, and IgG4 showed little or no affect on Clq binding 
(D). Each protein was tested in quadruplicate and in two or more inde- 
pendent assays. Error bars represent the variation between assays. 
Figure 3.  Three-dimensional structure of human IgG1 Fc. Amino  acids 
that are discussed in the text are darkened and indicated by arrows. Ala327 
is buried within the molecule. For clarity, one H chain is shaded slightly 
more than the other and associated carbohydrates are shaded like the op- 
posing H chain. The graphic is based on the coordinates from Diesenhofer 
(23) and was produced using the program Maclmdad (Molecular Applica- 
tions Group,  Stanford University, Stanford, CA). 
binding ability of the molecule (Figs. 2 and 5). When the 
reciprocal substitution was made in IgG4 (IgG4[Ala330]) the 
Ab remained unable to activate complement or bind Clq. 
Similarly,  substitution of the polymorphic residue  at posi- 
tion 296 (IgG4[Tyr296]) left the molecule deficient in its ability 
to activate complement. Thus, we find no evidence that resi- 
dues 296 or 330 determine isotype-specific differences in com- 
plement activation. 
ecule,  IgG1/4(Pro331),  also  binds  Clq  and is  even more 
efficient in complement-mediated lysis than IgG4(Pro331). 
To further prove that Pro331 is critical for complement acti- 
vation, we created Ser331 mutants of both IgG1 and IgG3. 
The substitution of Ser  for Pro  at  position 331  in IgG1 
(IgGl[Ser331])  results in complete loss of the ability to carry 
out complement-mediated hemolysis (Fig.  4  B).  It  is  in- 
teresting, however, that the molecule binds Clq as well as 
IgG1/4(Pro 331) (Fig. 2), which is quite effective in carrying 
out complement-mediated  hemolysis (Fig. 4). The same sub- 
stitution in IgG3 (IgG3[Ser331]) also profoundly  impairs, but 
does not abolish, its ability to carry out complement-mediated 
hemolysis,  and reduces its Clq binding to the intermediate 
level characteristic  of IgG1/4(Pro331),  IgG4(Pro331),  and 
IgGl(Ser331). 
Other  Polymorphic  Residues  in IgG1 and IgG4.  Although 
the replacement of Set 331 with Pro in IgG4 partially re- 
stores its activity,  IgG4(Pro331)  is still far less ef~dent than 
wild-type IgG1 in activating complement. Thus, additional 
mutant proteins were made to investigate the role of other 
residues  polymorphic between the two isotypes.  Substitu- 
tion of Set for Ala are residue 330 in IgG1 (IgGl[Ser330]) 
did not significantly alter the complement activating or Clq 
Discussion 
Activation of complement through the classical pathway 
is initiated by the interaction of Clq and IgG or IgM in an 
immune complex. Previous studies (8-10) have indicated that 
the C.2 domain of the H  chain of IgG contains structures 
critical  for complement activation and  that  complement- 
activating capacities can be transferred  between active and 
inactive IgG subclasses with Ca2,  whereas the exchange of 
C.1, hinge, or Ca3 produces little or no effect (7,  13,  14). 
Three possible C1 binding sites have been proposed: His285- 
Arg292 (19), the residues on the last two antiparatld fl strands 
(20), and Lys290-Glu295 (21). Based on protein engineering 
studies of mouse IgG2b, three charged amino acids (Glu318, 
Lys320, and Lys322) located on one fl strand of C.2 were 
proposed as constituting the essential Clq binding motif  (22). 
However,  this core binding motif is conserved in all four 
human IgG subclasses  that exhibit dramatic differences  in com- 
plement activation, including IgG4, which is completely in- 
active and does not bind Clq. Clearly, additional structural 
elements must determine the isotype-specific differences in 
IgG-complement interaction. We have now focused our at- 
tention  on  the  polymorphic amino  acids  located  in  Ca2 
which may determine these differences. 
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Figure 4.  Complement-mediated  hemolysis  by IgG wild-type  and po- 
sition 331 mutants. (.4) IgG4 and the IgG1/4 hybrid show no activity. 
However, substitution of Pro for Set at position 331 results in Abs now 
capable of directing lysis. (B) Substitution of Set for Pro at position 331 
severely  impairs the ability  of IgG3 to direct  ]ysis  and completely  abolishes 
IgG1 activity. 
IgG3, which is more efficient than IgG1 in complement 
consumption and complement-mediated cell lysis  (2,  12), 
differs in C.2 from IgG1 at only four amino acids (Table 1). 
In the three-dimensional structure (23), residue 276 is in close 
contact with the proposed 318-320-322  Clq binding motif 
(Fig. 3), and it is conceivable that the charged side chain of 
Lys276 in IgG3 contributes to the Clq-IgG interaction. In 
fact, we found that substitution of Lys276 with Asn in IgG3 
(IgG3[Asn276]) reduces its complement-activating capacity 
to the level seen in IgG1. However, the reciprocal change in 
IgG1 (IgGl[Lys276]) does not increase its activity. Instead, 
the mutant Ab is somewhat impaired in its capacity to mediate 
cell lysis. Furthermore, although both mutations affect com- 
plement-mediated cell lysis, neither has a significant effect 
on Clq binding.  These results suggest that the side chain 
of Lys276 is involved in some subsequent Ab-dependent step 
of the cascade and that in the context of IgG1, it does not 
assume a proper configuration for effective complement acti- 
vation. Similarly, mutation at residue 291 in IgG1 from Pro 
to Leu (as found in IgG3) decreases its ability to activate com- 
plement without affecting Clq binding,  again illustrating 
60. 
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Figure  5.  Complement-mediated  hemolysis  by wild-tyl~  and point mu- 
tants of  IgG1 and I~o4. Mutating  position 330 of I$G1 to resemble  IgG4 
does not affect  the ability of the molecule  to direct lysis. Similarly,  IgG1- 
like position 296 and 330 mutants of lg~ remain completely  inactive. 
the importance of the context of the entire domain in deter- 
mining the contribution of specific residues. 
Human IgG4 is unable to bind Clq and is incapable of 
complement activation. It has been postulated that either re- 
duced segmental flexibility (2, 5) or steric hindrance by Fab 
arms (24) caused by a short, rigid IgG4 hinge was respon- 
sible for the inactivity. However, recent Ab engineering ex- 
periments by us and others (6, 8) have provided evidence against 
this hypothesis. An IgG4 molecule with the flexible hinge 
region of IgG3 fails to bind Clq or activate complement, 
indicating that a structural lesion other than the rigid hinge 
leads  to the inactivity of IgG4.  By intra-domain exchange 
between IgG1 and IgG4 we have located the structures respon- 
sible for the inactivity of IgG4 to the COOH-terminal part 
of C.2 (from residue 292-340)  (13). We now show that res- 
idue 331 is a critical amino acid for determining the isotypic 
differences in complement activation. Substitution of Ser331 
with Pro in IgG4 or the IgG1/4 hybrid results in Abs now 
capable of binding Clq and of complement-mediated lysis. 
In addition, the reciprocal exchange of Pro331 to Ser in IgG3 
or IgG1 dramatically decreases or completely abolishes the 
capacity to activate complement. Residue 331 lies in a pep- 
tide loop between the last two ~/strands of C.2 and is in 
close proximity to the 318-320-322  Clq binding motif. It 
is feasible that Pro331  is either part of the Clq binding site 
or is required for maintaining the appropriate structures for 
Clq-IgG interaction. Moreover, Pro436 in C/~3 is analogous 
to Pro331  in C3~2 and a mutant IgM Ab with Pro436-~Ser 
showed a >50-fold reduction in complement activity (25). 
This observation further supports a critical role for Pro331. 
It is interesting that the Pro331-~Ser mutation in IgG3 also 
caused a 10-fold reduction in its affinity for the human high 
affinity Fc3~ receptor (26).  Therefore, the presence of Pro at 
residue 331 is important for both complement activation and 
Fc receptor binding. 
The IgG1 (Ser331) mutant is of particular interest because, 
although it binds Clq, it fails to carry out lysis, demonstrating 
665  Tao et al. dearly that Clq binding alone is not sufficient for comple- 
ment activation. This conclusion is supported by previous 
results in which a mutant of IgG3 lacking carbohydrate in 
C.2  could bind Clq but not consume complement (12). 
Our results suggest that amino acids other than Pro331 and 
polymorphic between IgG1 and IgG3 are important for Ab- 
dependent steps  of the  complement cascade besides  Clq 
binding. A good candidate in this case is residue 274 since 
both 3'3 and 3'4 have Gin (neutral) in this position and 3'1 
has Lys (positive).  Additional Ab-dependent steps that have 
been proposed and at which specific differences between IgG1 
and IgG3 have been found are the deposition of C3 and C4 
(27). 
It is noteworthy that Ser331--~Pro substitution in IgG4 
or in IgG1/4 does not result in Abs as effective as IgG1 in 
complement activation or Clq binding. The hierarchy of ac- 
tivity is IgG1 >  IgG1/4(Pro331) >  IgG4(Pro331).  Clearly, 
additional structural features of these molecules contribute 
to their different capacities. As shown in Table 1, IgG1 and 
IgG1/4(Pro331) are identical except for C.3 and three poly- 
morphic residues within CH2: Tyr296Phe,  Ala327Gly,  and 
Ala330Ser. Residue 327 is mostly buried inside the molecule 
and is probably not directly involved in Clq binding. Residues 
296 and 330 are exposed on the outer surface of the CH2 do- 
main (Fig. 3) and thus could be directly involved in comple- 
ment-IgG interaction. Single amino acid substitutions at res- 
idue 296 or 330 in IgG4 however, did not have any effect 
on complement activation or Clq binding. Also, substitu- 
tion ofa Ser at position 330 in IgG1 did not decrease its ability 
to activate complement or lower its level of Clq binding. 
This result implies that the different activities  of IgG1 and 
IgG1/4(Pro331) may be due to the combinatorial effect of 
these polymorphic residues. Introduction of multiple muta- 
tions at these residues  should clarify  this issue. 
The fact that IgG1/4(Pro331) is more active than IgG4- 
(Pro331)  in the direct lysis assay indicates  that the NH2- 
terminal part of the H chain also plays a role in determining 
isotype-specific  differences in complement activation.  The 
hinge region may contribute to this difference. In addition, 
three residues polymorphic  between IgG1 and igG4, Leu234 
Phe, His268 Gin, and Lys274 Gin, are present in this portion 
of C.2. Residue 234 is part of the lower hinge region and 
has been shown to be critical  for Fc receptor binding (26, 
28). However, we found that IgG4(Leu234) is unable to trigger 
complement activation  and  the  reciprocal  change,  IgG3 
(Phe234),  is almost as active as wild-type IgG3 (29).  The 
involvement of residue  274 in complement activation was 
thought to be unlikely since a mutation at this residue  in 
murine IgG2b did not alter its activity (22). Moreover,  the 
same amino acid, Gin, is found in both complement-active 
IgG3 and complement-inactive  IgG4. In light of our results, 
however, this residue does warrant investigation. Residue 268 
also seems to be a good candidate.  As shown in Fig. 3, its 
side chain is exposed on the outer surface of C.2 and a posi- 
tively charged His present at this residue in IgG1 and IgG3 
is substituted by a neutral Gin in IgG4. 
The present study has demonstrated that multiple amino 
acids within the C.2 domain determine the relative potency 
of the different human IgG isotypes in complement activa- 
tion. We have shown that a single amino acid substitution 
(Ser331--~Pro) in complement-deficient IgG4 is sufficient to 
impart some ability to bind Clq and activate complement 
and that the reciprocal mutations in IgG1 and IgG3 decrease 
their ability to bind Clq and to direct complement-mediated 
lysis. We have also produced several mutant Abs in which 
there is not a direct correlation between the ability to bind 
Clq and the ability to effect complement-mediated hemol- 
ysis. IgGl(Ser331),  in particular,  binds Clq but is incapable 
of complement-mediated hemolysis. These mutants provide 
compelling evidence  for  the  existence  of additional  Ab- 
dependent steps in the classical pathway of complement acti- 
vation. In addition, we have found that whereas it is rela- 
tively straightforward to produce Abs with reduced or loss 
of ability to activate complement, it much more of a chal- 
lenge to produce genetically engineered Abs with improved 
ability to activate complement. Amino acid substitutions at 
one location can cause distortion of local,  sometimes even 
distal three-dimensional structure. Thus, whereas loss of func- 
tion of mutants may support the importance of specific  residues 
as direct contacts for interacting molecules, they do not ex- 
clude the possibility that the residues may function instead 
by influencing the conformation of the binding site located 
elsewhere  in the molecule. The importance of residue 331 
in IgG--complement interaction has been demonstrated here 
by the inactivity of IgGl(Ser331)  and IgG4/l(Ser331), but 
most convincingly by the acquisition of activity by IgG4 
(Pro331) and IgG1/4(Pro331). Results obtained from this type 
of functional analysis of Ab molecules will facilitate the de- 
sign of Igs that exhibit optimal combinations of effector func- 
tions allowing for more specific and defined manipulation 
of the immune system. 
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